InvestorsHub Logo
Followers 17
Posts 2115
Boards Moderated 0
Alias Born 06/18/2007

Re: Vaffan-Coulo post# 13255

Thursday, 11/12/2015 7:07:57 AM

Thursday, November 12, 2015 7:07:57 AM

Post# of 15274
Calmare Therapeutics Incorporated Appoints Stephen J. D’Amato, M.D., F.A.C.E.P. Chief Medical Officer

The Company does not have an employment agreement with D'Amato. However, in connection with D'Amato's appointment, the Company and D'Amato have agreed to terms to be memorialized in an agreement. Under the agreed upon terms of the term sheet, Dr. D'Amato's compensation includes a base salary of One Hundred and Eighty Thousand Dollars ($180,000) per annum, bonus eligibility equal to forty percent (40%) of Dr. D'Amato's base salary, payable annually, subject to meeting goals and objectives created by the Company's Board of Directors. Additionally, Dr. D'Amato shall be granted three hundred thousand (300,000) stock options. These terms are subject to modification until a formal employment agreement is executed.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.